pharma · Androgenetic Alopecia · Acute Myocardial Infarction
Dong Wang
Dong Wang is a pharma organization headquartered in CN. Primary therapeutic focus areas include Androgenetic Alopecia, Acute Myocardial Infarction, Type 2 Diabetes Mellitus, Postmenopausal Osteoporosis, Alzheimer's Disea
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 8
- Drugs
- 13
- Patents
- 0
Risedronate Sodium 35 MG [Actonel]
Approved · small molecule · Postmenopausal Osteoporosis
Risedronate Sodium 35 MG [Actonel] for Postmenopausal Osteoporosis is a Approved program (small_molecule) at Dong Wang with 1 ClinicalTrials.gov record(s).
Internal code ATN_PMO_IV
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Dong Wang
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Postmenopausal Osteoporosis
- Status
- completed
- Trials
- 1